Title of Invention	A PHARMACEUTICAL COMPOSITION COMPRISING RALOXIFENE, A SURFACTANT AND A WATERSOLUBLE DILUENT.
Abstract	This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.

Full Text

FIELD OF THE INVENTION The present invention relates to an orally administrable pharmaceutical formulation comprising raloxifene, its ethers or esters, or a pharmaceutically acceptable salt thereof, in combination with a hydrophilic carrier composition. BACKGROUND OF THE PRIOR ART Certain benzothiophenes of the formula wherein R and R1 are independently hydrogen, COR2, or R3; R1 is hydrogen, C1-C14 alkyl, C1-C9 chloroalkyl, C1-C3 fluorcalkyl, C5-C7 cycloalkyl, C1-C4 alkoxy, phenyl, or phenyl mono- cr disubstituted with C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, chlorc, fluoro, cr trichloro or fluoro) methyl; R3 is C1-C3 alkyl, C5-C7 cycloalkyl, or benzyl; or a pharmaceutically-acceptable salt thereof; are nonsteriodal antiestrogens and antiandrogens. These compounds are useful in the treatment, of mammary and prostatic tumors, and in the treatment of mammary and prostatic fibrocystic disease. The formula I compounds are described in U.S. Patent No. 4,418,068 (issued November 29, 1983) . This patent described the preparation of these compounds, as well as their use for antiestrogen and antiandrogen therapy. The preparation of pharmaceutical compositions for antiestrogenic and antiandrogenic therapy was also described. Raloxifene, which is 6-hydroxy-2- (4-hydroxyphenyl)-3 - [4- (2 - piperidinoethoxy)benzoyl]benzo [b]thiophene, is a particulary useful compound from this series of benzothiophenes. Raloxifene competitively inhibits estrogen action in a number of in vitro and in vivo models. Black,- Jones, and Falcone, Life Sci., 32, 1031-1036 (1983); Knecht, Tsai-Morris, and Catt, Endocrinology, 116, 1771-1777 (1985); • and Sirnard and Labrie, Mol. Cell. Endocrinology, 39, 141-144 (1985). This compound also displays some estrogen-like actions in addition to its estrogen-antagonistic effects. Ortmann, Emons, Knuppen, and Catt, Endocrinology, 123, 962-963 (1988). A recent report suggests that raloxifene is useful in the treatment of osteoporosis in postmenopausal women. Turner, Sato, and Bryant, Journal of Clinical Investigation (In Press). The formula I compounds may be administered as pharmaceutically-acceptable salts. A particularly useful pharmaceutically-acceptable salt of raloxifene is the hydrochloride salt. This salt form is easily prepared by the addition of hydrogen chloride to a solution of raloxifene in an organic solvent, such as tetrahydrofuran or methanol. Aqueous solubility of raloxifene hydrochloride, however, is far below what would be expected for an organic hydrochloride salt containing two phenolic hydroxyl groups. This poor solubility has somewhat limited the bioavailability of this preferred salt form. Another significant barrier to optimum and consistent absorption of raloxifene hydrochloride is its hydrophobicity. STATEMENT OF THE INVENTION Accordingly, the present invention relates to a pharmaceutical composition comprising raloxifene, its esters or ethers, in combination with a surfactant and a water-soluble diluent and optionally a lubricant, disintegrant, hydrophilic binder and a film coating. SUMMARY OF THE INVENTION To overcome the limited bioavailability, the present invention provides orally administerable pharmaceutical formulations comprising raloxifene, its esters or ethers, or a pharmaceutically- acceptable salt thereof, in combination with a hydrophilic carrier composition, such formulations having increased solubility in aqueous media. More particularly, the present invention provides an orally administerable pharmaceutical formulation comprising raloxifene, its esters or ethers, or a pharmaceutically-acceptable salt thereof, in combination with a surfactant, a water-soluble diluent, and optionally a hydrophilic binder. The present invention also provides pharmaceutical formulations further comprising a lubricant and a disintegrant. DETAILED DESCRIPTION The present invention provides orally administerable pharmaceutical formulations comprising raloxifene, its esters or ethers, or a pharmaceutically-acceptable salt thereof, in combination with a surfactant, a water-soluble diluent, and optionally a hydrophilic binder. Raloxifene, its esters, and its ethers are represented by the following formula: wherein R and R1 are independently hydrogen, COR2, or R2; R2 is hydrogen, C1-C14, alkyl, C1-C3 chloroalkyl, C1—C3 fluoroalkyl, C5-C7 cycloalkyl, C1-C4 alkoxy, phenyl, or phenyl mono- or disubstituted with C2-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, chloro, fluoro, or tri(chloro or fluoro)methyl; R3 is C1-C4 alkyl, C5-C7 cycloalkyl, or benzyl. Raloxifene is the compound wherein R and R1 are hydrogen. The preparation of this compound is described in U.S. Patent No. 4,418,068, which is incorporated herein by reference. A pharmaceutical chemist will readily recognize that this compound can be effectively administered as an ether or ester, formed on either one or both of the phenolic hydroxyl groups. The preparation of these esters and ethers is also described in U.S. Patent No. 4,418,068. The general chemical terms used in the above formula have their usual meanings. The term "C1-C14 alkyl" represents a straight or branched alkyl chain having from one to 14 carbon atoms. Typical C1-C14 alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, n-hexyl, 2-methylpentyl, n-octyl, decyl, 2-methyldecyl, 2,2- dimethyldecyl, undecyl, dodecyl, and the like. The term "C1-C14 alkyl" includes within it the term "C1-C4 alkyl". Typical C1-C4 alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and t-butyl. The terms "C1-C3 chloroalkyl" and "C1-C3 fluoroalkyl" represent methyl, ethyl, propyl, and isopropyl substituted to any degree with chlorine or florine atoms, from one atom to full substitution. Typical C1-C3 chloroalkyl groups include chloromethyl, dichloromethyl, trichloromethyl, 2- chlorethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 1,2- dichloroethyl, 1,1,2,2-tetrachloroethyl, 1,2,2,2- tetrachloroethyl, pentachlorethyl, 3-chloropropyl, 2- chloropropyl, 3,3-dichloropropyl, 2,3-dichloropropyl, 2,2- dichloropropyl, 3,3,3-trichloropropyl, and 2,2,3,3,3- pentachloropropvl. Typical C1-C3 fluoroalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, 2- fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 1,2- difluoroethyl, 1,1,2,2-tetrafluoroethyl, 1,2,2,2- tetrafluoroethyl, pentafluoroethyl, 3-fluoropropyl, 2- fluoropropyl, 3,3-difluoropropyl, 2,3-difluoropropyl, 2,2- difluoropropyl, 3,3,3-trifluoropropyl, and 2,2,3,3,3- pentafluoropropyl. The term "C5-C7 cycloalkyl" represents cyclic hydrocarbon groups containing from five to seven carbon atoms. The C5-C7 cycloalkyl groups are cyclopentyl, cyclohexyl, and cycloheptyl. The term "C1-C4 alkoxy" represents groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, and the like groups. The term "pharmaceutically-acceptable salt" represents salt forms of raloxifene, its esters, or its ethers that are physiologically suitable for pharmaceutical use. The pharmaceutically-acceptable salts can exist in conjunction with raioxifene, its esters, or its ethers as acid addition primary, secondary, tertiary, or quaternary ammonium, alkali metal, or alkaline earth metal salts. Generally, the acid addition salts are prepared by the reaction of an acid with a compound of formula I, wherein R, R1, R2, and R3, are as defined previously. The alkali metal and alkaline earth metal salts are generally prepared by the reaction of the metal hydroxide of the desired metal salt with a compound of formula I, wherein at least one of R and R1 is hydrogen. Acids commonly employed to form such acid addition salts include organic acids such as hydrochloric, hydrobromic, hydriodic, sulfuric, and phosphoric acid, as well as organic acids such as toluenesulfonic, methanesulfonic, oxalic, para-bromophenylsulfonic, carbonic, succinic, citric, benzoic, and acetic acid, and related inorganic and organic acids. Such pharmaceutically-acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, ammonium, monohydrogen phosphate, dihydrogen phosphate, meta-phosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprolate, acrylate, formate, isobutyrate, caprate, heptanoate, propionate, oxalate, malonate, succinate, subarate, sebacate, fumarate, hippurate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, a-hydroxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate, ammonium, magnesium, tetramethylammonium, potassium, trimethylammonium, sodium, methylammonium, calcium, and the like salts. The term "hydrophilic binder" represents binders commonly used in the formulation of Pharmaceuticals, such as polyvinyipyrrolidone, polyethylene glycol, sucrose, dextrose, corn syrup, polysaccharides (including acacia, tragacanth, guar, and alginates), gelatin, and cellulose derivatives (including hydroxypropyl methylcellulose, hydroxypropyl cellulose, and sodium carboxymethylcellulose). The term "surfactant", as used herein, represents ionic and nonionic surfactants or wetting agents commonly used in the formulation of Pharmaceuticals, such as ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives, monoglycerides or ethoxylated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, sodium docusate, sodium laurylsulfate, cholic acid or derivatives thereof, lecithins, and phospholipids. The term "water-soluble diluent" represents compounds typically used in the formulation of Pharmaceuticals, such as sugars (including lactose, sucrose, and dextrose), polysaccharides (including dextrates and maltodextrin), polyols (including mannitol, xylitol, and sorbitol), and cyclodextrins. The term "disintegrant" represents compounds such as starches, clays, celluloses, alginates, gums, cross-linked polymers (such as cross-linked polyvinylpyrrolidone and cross-linked sodium carboxymethylcellulose), sodium starch glycolate, low-substituted hydroxypropyl cellulose, and soy polysaccharides. Preferably the disintegrant is a cross- linked polymer, more preferably cross-linked polyvinylpyrrolidone. The term "lubricant" represents compounds frequently used as lubricants or glidants in the preparation of phax~maceuticals, such as talc, magnesium stearate, calcium stearate, stearic acid, colloidal silicon dioxide, magnesium carbonate, magnesium oxide, calcium silicate, microcrystalline cellulose, starches, mineral oil, waxes, glyceryl behenate, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, sodium laurylsulfate, sodium stearyl fumarate, and hydrogenated vegetable oils. Preferably the lubricant is magnesium stearate or stearic acid, more preferably magnesium stearate. While all of the formulations of the present invention have increased solubility in aqueous media and, therefore, greater bioavailability would be expected, certain formulations are preferred. Preferably, the surfactant is an anionic or nonionic surfactant. Representative surfactants from this preferred group include sodium laurylsulfate, sodium docusate, ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives, monoglycerides or ethoxylated derivatives thereof, and diglycerides or polyoxyethylene derivatives thereof. Preferably, the water-soluble diluent is a sugar or polyol. When a hydrophilic binder is present, preferably the binder is sucrose, dextrose, corn syrup, gelatin, a cellulose derivative, or polyvinylpyrrolidone. Certain formulations of the present invention are more preferred. More preferably, the surfactant is a nonionic surfactant, such as ethoxylated castor oil, polyglycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives, monoglycerides or echoxylated derivatives thereof, and diglycerides or polyoxyethylene derivatives thereof. More preferably, the water-soluble diluent is a sugar, such as lactose, sucrose, and dextrose. More preferably, the hydrophilic binder is a cellulose derivative or polyvinylpyrrolidone. Certain formulations of the present invention are most preferred. Most preferably, the surfactant is a polyoxyethylene sorbitan fatty acid ester, such as polysorbate 80. Most preferably, the water-soluble diluent is lactose. Most preferably the hydrophilic binder, when present, is polyvinylpyrrolidone. The orally administerable compositions of the present invention are prepared and administered according to methods well known in pharmaceutical chemistry. See Remington's Pharmaceutical Sciences, 17th ed. (A. Osol ed., 1985). For example, the compositions of the present invention may be adminstered by means of solid dosage forms such as tablets and capsules. Preferably, the compositions are formulated as tablets. These tablets are prepared by wet granulation, by dry granulation, or by direct compression. Tablets for this invention are prepared utilizing conventional tabletting techniques. A general method of manufacture involves blending raloxifene, its ester, ether, or a salt thereof, the water-soluble diluent, and optionally a portion of a disintegrant. This blend is then granulated with a solution of the hydrophilic binder and surfactant in water and/or organic solvent, such as methanol, ethanol, isopropanol, methylene chloride, and acetone, and milled if necessary. The granules are dried and reduced to a suitable size. Any other ingredients, such as lubricants, (e.g. magnesium stearate) and additional disintegrant, are added to the granules and mixed. This mixture is then compressed into a suitable size and shape using conventional tabletting machines such as a rotary tablet press. The tablets may be film coated by techniques well known in the art. Capsules for this invention are prepared utilizing conventional encapsulating methods. A general method of manufacture involves blending raloxifene, its ester, ether, or salt thereof, the water-soluble diluent, and optionally a portion of a disintegrant. This blend is then granulated with a solution of the hydrophilic binder and surfactant in water and/or organic solvent, and milled if necessary. The granules are dried and reduced to a suitable size. Any other ingredients, such as a lubricant (e.g. colloidal silicon dioxide) are added to the granules and mixed. The resulting mixture is then filled into a suitable size hard- shell gelatin capsule using conventional capsule-filling machines. The following formulation examples are illustrative only and are not intended to limit the scope of the invention in any way. Tablets may be prepared using the ingredients and procedures as described below: The mixture of raloxifene HCl, lactose, and a portion of the cross-linked polyvinylpyrrolidone is granulated with an aqueous solution of the polyvinylpyrrolidone and polysorbate 80. The granules are dried, reduced to a suitable size, and mixed with stearic acid, magnesium stearate, and remaining cross-linked polyvinylpyrrolidone. The mixture is compressed into individual tablets yielding a tablet weight of 525 mg. The mixture of raloxifene HCl, lactose anhydrous, dextrose, and a portion of the cross-linked polyvinylpyrrolidone is granulated with an alcoholic solution of polyvinylpyrrolidone and polysorbate 80. The granules are dried, reduced to a suitable size, and mixed with magnesium stearate, stearic acid, and remaining cross- linked polyvinylpyrrolidone. The mixture is compressed into individual tablets yielding a tablet weight of 525 mg. The mixture of raloxifene HCl, dextrose, and cross- linked sodium carboxymethylcellulose is granulated with an aqueous solution of hydroxypropyl cellulose and sodium laurylsulfate. The granules are dried, reduced to a suitable size, and mixed with magnesium stearate. The mixture is compressed into individual tablets yielding a tablet weight of 400 mg. The mixture of raloxifene HCl, lactose anhydrous, spray-dried hydrous lactose, and a portion of the cross- linked polyvinylpyrrolidone is granulated with an aqueous solution of polyvinylpyrrolidone and polysorbate 80. The granules are dried, reduced to a suitable size, and mixed with magnesium stearate and remaining cross-linked polyvinylpyrrolidone. The mixture is compressed into individual tablets yielding a tablet weight of 240 mg. The mixture of raloxifene HCl, anhydrous lactose, and cross-linked sodium carboxymethylcellulose is granulated with an aqueous solution of poloxamer and hydroxypropyl cellulose. The granules are dried, reduced to a suitable size, and mixed with stearic acid and magnesium stearate. The mixture is then compressed into individual tablets yielding a tablet weight of 240 mg. The mixture of raloxifene HCl, lactose, dextrose, and cross-linked polyvinylpyrrolidone is granulated with an aqueous solution of hydroxypropyl methylcellulose and sodium laurylsulfate. The granules are dried, reduced to a suitable size, and mixed with the stearic acid. The mixture is then compressed into individual tablets yielding a tablet weight of 240 mg. The mixture of raloxifene HCl, lactose anhydrous, and cross-linked polyvinylpyrrolidone is granulated with an aqueous solution of polyvinylpyrrolidone and polysorbate 80. The granules are dried, reduced to a suitable size, and mixed with magnesium stearate. The mixture is then compressed into individual tablets yielding a tablet weight of 240 mg. The mixture of raloxifene HCl, lactose anhydrous, spray-dried hydrous lactose, and a portion of the cross- linked polyvinylpyrrolidone is granulated with an aqueous solution of polyvinylpyrrolidone and polysorbate 80. The granules are dried, reduced to a suitable size, and mixed with magnesium stearate and remaining cross-linked polyvinylpyrrolidone. The mixture is then compressed into individual tablets yielding a tablet weight of 240 mg. The mixture of raloxifene HC1, mannitol, dextrose, and sodium starch glycolate is granulated with an aqueous solution of polysorbate SO and hydroxypropyl methylcellulose. The granules are dried, reduced to a suitable size, and mixed with stearic acid and magnesium stearate. The mixture is then compressed into individual tablets yielding a tablet weight of 240 mg. The mixture of raloxifene HCl, anhydrous lactose, hydrous spray-dried lactose, and a portion of the cross- linked polyvinylpyrrolidone is granulated with an aqueous solution of polyvinylpyrrolidone and polysorbate 80. The granules are dried, reduced to a suitable size, and mixed with magnesium stearate and the remaining cross-linked polyvinylpyrrolidone. The mixture is then compressed into individual tablets yielding a tablet weight of 230 mg. The mixture of raloxifene HCl, hydrous spray-dried lactose, and a portion of the cross-linked polyvinylpyrrolidone is granulated with an aqueous solution of polyvinylpyrrolidone and polysorbate 80. The granules are dried, reduced to a suitable size and mixed with magnesium stearate and remaining cross-linked polyvinylpyrrolidone. The mixture is then compressed into individual tablets yielding a tablet weight of 230 mg. The mixture of raloxifene HCl and anhydrous lactose is granulated with an aqueous solution of polysorbate 80 and poiyvinylpyrrolidone. The granules are dried, reduced to a suitable size, and mixed with the polyethylene glycol 8000. The mixture is then compressed into individual tablets yielding a tablet weight of 230 mg. Capsules may be prepared using the ingredients and procedures as described below: The mixture of raloxifene HCl, hydrous spray-dried lactose, and cross-linked poiyvinylpyrrolidone is granulated with an aqueous solution of sodium laurylsulfate and hydroxypropyl methylcellulose. The granules are dried, reduced to a suitable size, and mixed with colloidal silicon dioxide. This mixture is then filled into Size 3 hard-shell gelatin capsules utilizing conventional encapsulating equipment, with each capsule containing 23 0 mg of the final mixture. The mixture of raloxifene HCl, hydrous spray-dried lactose, and cross-linked polyvinylpyrrolidone is granulated with an aqueous solution of sodium laurylsulfate and hydroxypropyl methylcellulose. The granules are dried, reduced to a suitable size, and mixed with colloidal silicon dioxide. This mixture is then filled into Size 3 hard-shell gelatin capsules utilizing conventional encapsulating equipment, with each capsule containing 23 0 mg of the final mixture. The mixture of raloxifene HCl, hydrous spray-dried lactose, and cross-linked polyvinylpyrrolidone is granulated v/ith an aqueous solution of sodium laurylsulfate and hydroxypropyi methvlcellulose. The granules are dried, reduced to a suitable size, and mixed v/ith colloidal silicon dioxide. This mixture is then filled into Size 3 hard-shell gelatin capsules utilizing conventional encapsulating equipment, with each capsule containing 230 mg of the final mixture. We Claim: 1. An orally administerable pharmaceutical formulation consisting essentially of raloxifene hydrochloride, in combination with a surfactant, polyvinylpyrrolidone and a water-soluble diluent, wherein: the surfactant is selected from the group consisting of sodium docusate, ethoxylated castor oil, polyglyucolysed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers. polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives, monoglycerides or ethoxylated derivatives threreof, and diglycerides or polyoxyethylene derivatives thereof; and the water-soluble diluent is a polyol or sugar, 2. The formulation as claimed in claim 1, wherein the surfactant is a polyoxyethylene sorbitan fatty acid ester. 3. The formulation as claimed in claim 1 or 2, wherein the surfactant is polysorbate 80. 4. The formulation as claimed in claim 1 to 3, wherein the water-soluble diluent is a 5. The formulation as claimed in any one of claims 1 to 4, wherein the water-soluble diluent is lactose. 6. The formulation as claimed in any one of claims 1 to 5, further comprising a lubricant and a disintegrant. 7. The formulation as claimed in claim 6, wherein the lubricant is magnesium stearate or stearic acid, and the disintegrant is cross-linked polyvinylpyrrolidone. 8. An orally administerable pharmaceutical formulation consisting essentially of raloxifene hydrochloride in combination with polysorbate 80, cross-linked polyvinylpyrrolidone, lactose, polyvinylpyrrolidone and magnesium stearate. 9. The formulation as claimed in any one of claims 1 to 8 further comprising a film coating. This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.

Documents:

184-CAL-1995-(14-02-2012)-FORM-27.pdf

184-CAL-1995-(14-02-2012)-FORM-27a..pdf

184-cal-1995-granted-abstract.pdf

184-cal-1995-granted-assignment.pdf

184-cal-1995-granted-claims.pdf

184-cal-1995-granted-correspondence.pdf

184-cal-1995-granted-description (complete).pdf

184-cal-1995-granted-examination report.pdf

184-cal-1995-granted-form 1.pdf

184-cal-1995-granted-form 13.pdf

184-cal-1995-granted-form 18.pdf

184-cal-1995-granted-form 2.pdf

184-cal-1995-granted-form 26.pdf

184-cal-1995-granted-form 3.pdf

184-cal-1995-granted-form 5.pdf

184-cal-1995-granted-reply to examination report.pdf

184-cal-1995-granted-specification.pdf